Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Walgreens, the nation’s largest drugstore chain and an industry leader with more than 17,000 certified or licensed immunizers, today announced it is offering H1N1 vaccine at more than 1,500 Walgreens pharmacies and select Take Care Clinics in 27 states, as well as the District of Columbia.
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius and senior HHS officials leading the H1N1 response at the Department will hold a press conference, at the National Press Club on Thursday, December 17, 2009.
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
Certified healthcare providers who have already immunized patients most at risk of complications from the H1N1 flu virus may now offer the vaccine to anyone who wants it, the Department of Health announced today.
An international team of Canadian and Spanish scientists have found the first potential immunological clue of why some people develop severe pneumonia when infected by the pandemic H1N1 virus.
Upp Technology, a global provider of IT staffing services, implemented its irms|EM™ (Emergency Management) software for the State of Vermont within three weeks of selection of the solution. The software helped the State’s RSS (Receive, Stage, & Store) Warehouse become operational following just one day of training and distribute more than 2,000 piece of H1N1 Personal Protection Equipment (PPE) inventory to hospitals throughout the state.
Estill Medical Technologies, Inc., a family-owned Texas company that produces the Thermal Angel Blood and IV Fluid Infusion Warmer, a patented medical device being utilized by U.S. hospitals, military and emergency responders to lessen the effects of fluid-induced hypothermia, named the CALSTAR 6 Unit of South Lake Tahoe as the first-ever recipient of their "Thermal Angel Lifesaver of the Year Award."
Safe Life Corp., an innovative antimicrobial company dedicated to developing novel technologies that prevent the spread of infection and disease, announced today that it is ramping production of its comfortable, breathable, A400 Series respirator to help healthcare providers and government agencies address the global shortage of N95 respirators during the H1N1 pandemic.
Dr. Bob Arnot kicks-off a national educational tour on the silent threat of H1N1 flu contaminated touch surfaces and the new biotechnology in EPA-registered SpectraSan 24 that kills bacteria, fungus and viruses including Influenza A (H1N1 or Swine Flu).
The federal Centers for Disease Control and Prevention, or CDC, has allocated a total of 3,177,900 doses of H1N1 flu vaccine to Pennsylvania to date, the state Department of Health said today.
As communities brace for rising wintertime influenza cases, scientists are developing a mathematical and visual analytic toolkit to help health officials quickly analyze pandemics and craft better response strategies.
DxNA announced today that the United States Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its 2009 H1N1 influenza virus diagnostic test for use in DxNA's GeneSTAT(TM) detection platform.
SinoFresh HealthCare Products, Inc. announced the recent successful initial pilot animal study of the SinoFresh Nasal Spray product for use in preventing and decreasing the severity of H1N1 ("swine flu") virus.
HIV-infected adults currently are being recruited to participate in a clinical trial of 2009 H1N1 influenza vaccine. The study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, will enroll approximately 240 men and women between the ages of 18 and 64.
PURE Bioscience, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported revenues for the fiscal quarter ended October 31, 2009 of $221,900 compared with revenues of $110,600 in the same quarter of the prior fiscal year.
U.S. health officials on Thursday announced nearly 10,000 people in the U.S. had died from H1N1 (swine flu) since the virus was first reported in April, the New York Times reports.
Hard to Treat Diseases (HTDS) http://www.htdsmedical.com the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about. While there are several significant pending transactions they are not ready to be announced yet, however will be in due and appropriate time.
A Virology Lab in Children’s Hospital No. 1 (CH1), Ho Chi Minh City, Vietnam, sponsored by National Cheng Kung University Hospital (NCKUH) and National Health Research Institutes (NHRI) in Taiwan was launched on November 11th, 2009.
Municipalities in Massachusetts should assume that the H1N1 Influenza is now present in their communities, schools, and work places, and should take appropriate precautions to prevent the spread of this virus as well as the seasonal flu.
The Department of Defense today issued an interim final rule designating pharmacies as providers for H1N1, seasonal flu and pneumonia vaccinations under its TRICARE program.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.